

# Newsletter July 2025

Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis



## Recruitment update

**Total recruitment to date: 4787**


OPTIMA Main - 4375 participants

OPTIMA prelim - 412 participants


|     |      |
|-----|------|
| UK* | 3644 |
| NOR | 501  |
| ANZ | 218  |
| THA | 12   |

*\*UK recruitment closed on 10th January 2025*

## Recruitment countdown:



## Path-For-Young update



We are excited to announce the launch of the Path-for-Young website and X account.


This EU-funded study unites 20+ partners to improve care for young women with hormone-dependent breast cancer at high risk of recurrence. The website provides further information on goals, partners, patient roles and news.

Please check out the links below!

[Path-For-Young Website](#)

[Path-For-Young X Account](#)

**Please note:** There is no further information about the UK involvement in Path-for-young at the moment. An investigator letter will be sent out in due course.



Optima-young  
A New Approach to Breast Cancer  
Treatment in Young Women

Path-for-young is based on a clinical trial recruiting premenopausal patients with HR+/HER2- breast cancer. This clinical trial, called Optima-young, aims to demonstrate that premenopausal patients with high-risk HR+/HER2- breast cancer and receiving optimal endocrine therapy can be stratified to forego adjuvant chemotherapy without detriment to clinical outcome and resulting in improved long-term quality of life. Click on the video to learn more about the Optima-young clinical trial.

## Per Patient Payments

All Sites have recently been contacted with a reminder about OPTIMA Per Patient Payments.

The OPTIMA trial provides a one-off payment of £124.42 per patient randomised to cover various locally incurred research costs by participating trusts. This payment may be claimed from the Sponsor (UCL) once all baseline participant information (ie CRF's #1 – #6) has been received by the OPTIMA Trial Office. To ensure an efficient payment procedure, please observe the following:

1. Invoices may be submitted quarterly as per the OPTIMA Trial Site Agreement. Please do not invoice more frequently.
2. The OPTIMA Trial Office can confirm which participants are eligible for payment claims if you are unsure\*
3. Invoice details:
  - The invoice must be addressed to University College London (UCL). University College London Hospitals NHS Foundation Trust is a different organisation and **invoices addressed to UCLH cannot be paid by UCL**.
  - The invoice must reference “**OPTIMA Trial, UCL Project Code 527781**” as without this information UCL is unable to identify the site budget and will not process the invoice.
  - Please include trial numbers (TNO's) of participants for whom payment is claimed.
  - No VAT is to be applied to invoices as these payments are outside the scope of VAT.
  - Invoices **do not require a UCL PO number**.

\*The OPTIMA Trial Office at Warwick Clinical Trials Unit has no role in the actual processing of invoices, so cannot confirm which patients have been invoiced for / which invoices have already been processed, or chase any overdue invoices.



Invoice queries should be sent to: [s.howells@ucl.ac.uk](mailto:s.howells@ucl.ac.uk) and [fin-post-awrd-admin@ucl.ac.uk](mailto:fin-post-awrd-admin@ucl.ac.uk), copied to [CI.OPTIMA-finance@ucl.ac.uk](mailto:CI.OPTIMA-finance@ucl.ac.uk)

Further information can be found in the “Invoicing for OPTIMA per patient payment” document within your OPTIMA ISF.

**OPTIMA Trials Team:** 02476 151057 | X: @OPTIMAbstudy

E-mail: [OPTIMA@warwick.ac.uk](mailto:OPTIMA@warwick.ac.uk) | Website: [optimabreaststudy.com](http://optimabreaststudy.com)